Although liver PPARγ expression is relatively low in basal conditions, it acts as a steatogenic factor [18] and its expression is upregulated in fatty liver diseases such as NAFLD, where it induces de novo lipogenesis and lipid accumulation [19]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.